Abstract 26P
Background
10% of colorectal cancers (CRC) have a BRAF mutation (BM). This is a poor prognostic group with distinct clinical characteristics. Robust preclinical models that reflect this CRC subtype are currently lacking. We have developed a novel, aggressive, immune competent, genetically engineered mouse model (GEMM) that aligns well with human BM CRC.
Methods
4 genes were targeted with the villinCreER: activating Braf V600E/+ (B), deletion of Trp53 fl/fl (P), deletion of ALK5fl/fl and NOTCH1 intracellular domain expression Rosa26 N1icd/+ (N). This generated BPNA mice. Mice were induced and aged until clinical endpoint. Clinically relevant treatments were benchmarked, including BRAFi (Dabrafenib) combined with EGFRi (Erlotinib). Mouse tumour organoids were derived and high throughput drug screening was performed.
Results
BPNA mice developed endpoint tumours in the proximal colon in a short time period (37 DPI). Mice had high rates of T4 disease (57%) and, despite short latency, developed peritoneal metastasis in 5/27 mice (19%). Primary tumours had proficient mismatch repair (pMMR). Tumours classified as CMS4, aligned with the BM1 transcriptional subtype and displayed regenerative cancer stem cell markers. Therapeutic interventions based on the BEACON CRC (BRAFi+EGFRi) combinations were tested. Both BRAFi and EGFRi as monotherapies had no significant survival advantage (OS) in vivo. However in combination, mice lived twice as long with median OS of the combination group 66 DPI vs 32 DPI in the vehicle control (log-rank p<0.001). DUSP6 was only significantly suppressed in the BRAF/EGFRi arm suggesting effective MAPK targeting requires combination therapy. Through organoid drug screening, 28/166 compounds were identified as hits of which 3/5 top hits were proteasome inhibitors.
Conclusions
The BPNA GEMM aligns with human disease in terms of primary tumour characteristics and metastatic pattern. Mice also respond to standard of care therapeutics similarly to humans creating a good benchmark for further investigation. Organoid drug screens have highlighted a potentially novel drug class for BM CRC treatment. Future work will utilize these mice to test therapeutics enabling robust pre-clinical evidence to de-risk future novel early phase trials for BM CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
O.J. Sansom: Financial Interests, Institutional, Funding: Novartis, Cancer Research Technology, Redx. All other authors have declared no conflicts of interest.
Resources from the same session
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09